Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 143 Show results per page	View Search Criteria \| Help With Results


1.		Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				40 to 90				Pharmaceutical / Industry				AVO108943 NCT00470834


2.		Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care, Treatment				Active				18 and over				Other				001-0015-211 NCT00127387

Last Modified: 1/14/2009 First Published: 9/1/2001


3.		Phase III Randomized Study of Consolidation Therapy With or Without Strontium Chloride Sr 89 After Induction Chemotherapy in Patients With Androgen-Independent Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Any age				NCI				MDA-ID-00156 NCI-3410, 3410, NCT00024167

Last Modified: 1/14/2009 First Published: 2/20/2004


4.		Phase III Randomized Study of Zoledronate for the Prevention of Skeletal-Related Events in Patients With Prostate Cancer and Bone Metastases Undergoing Androgen Deprivation Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				CALGB-90202 ECOG-CALGB-90202, NCT00079001, SWOG-CALGB-90202, CAN-NCIC-PRC2

Last Modified: 1/15/2009 First Published: 8/19/2005


5.		Phase III Randomized Study of Docetaxel and Prednisone With Versus Without Atrasentan in Patients With Hormone-Refractory Stage IV Prostate Cancer and Bone Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				SWOG-S0421 S0421, NCT00134056

Last Modified: 1/14/2009 First Published: 3/24/2006


6.		Phase III Randomized Study of Chemohormonal Therapy Versus Androgen Ablation Therapy in Patients With Extensive Metastatic Prostate Cancer [CHAARTED]

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				ECOG-E3805 E3805, NCT00309985

Last Modified: 7/30/2008 First Published: 6/9/2006


7.		Phase III Randomized Study of Pomegranate Extract in Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiotherapy for Localized Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				ROLL-GUP-0205-1 UCLA-0507059-01, NCT00336934


8.		Double-Blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				20050103 NCT00321620

Last Modified: 1/15/2009 First Published: 9/10/2006


9.		Phase III Randomized Study of Stereotactic Radiosurgery With Versus Without Whole-Brain Radiotherapy in Patients With Cerebral Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				NCCTG-N0574 N0574, ACOSOG-N0574, NCT00377156


10.		A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects With a Rising PSA

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				XRP6976J/3503 EudraCT#:2007-000323-17, NCT00514917

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute